|
|
 Previous Article | Table of Contents | Next Article 
The human myeloma cell line LP-1: a versatile model in which to study early
plasma-cell differentiation and c-myc activation
L Pegoraro, F Malavasi, G Bellone, M Massaia, M Boccadoro, G Saglio, A Guerrasio, G Benetton, L Lombardi and R Coda
Dipartmento di Genetica, Universita di Torino, Italy.
The characteristics of a human cell line (LP-1) derived from the peripheral
blood of a patient with IgG-lambda myeloma in leukemic transformation are
described. The cells resemble immature plasma cells in that they exhibit a
membrane phenotype that is intermediate between late B lymphocytes and
plasma cells, even though they secrete IgG- lambda chains. Treatment of
LP-1 cells with 12-0 tetradecanoylphorbol- 13-acetate (TPA) or pokeweek
mitogen (PWM) induces the appearance of surface markers and ultrastructural
features typical of mature plasma cells but does not affect their
proliferative activity. Molecular analysis of the cell line showed an
increased expression of the c-myc protooncogene and the presence of
abnormally sized transcripts. Conventional cytogenetics and pulsed-field
gel electrophoresis showed no structural rearrangements of the c-myc gene,
suggesting that the abnormal c-myc expression may be due to point mutations
or small deletions within the gene. The LP-1 cell line is a useful model in
which to study the process of B-cell maturation; such study may lead to the
uncovering of unusual mechanisms of c-myc activation. Furthermore, the LP-1
cell is a potential partner in the generation of human hybridomas.
Volume 73,
Issue 4,
pp. 1020-1027,
03/01/1989
Copyright © 1989 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
T. Stromberg, S. Ekman, L. Girnita, L. Y. Dimberg, O. Larsson, M. Axelson, J. Lennartsson, U. Hellman, K. Carlson, A. Osterborg, et al.
IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells
Blood,
January 15, 2006;
107(2):
669 - 678.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Stromberg, A. Dimberg, A. Hammarberg, K. Carlson, A. Osterborg, K. Nilsson, and H. Jernberg-Wiklund
Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone
Blood,
April 15, 2004;
103(8):
3138 - 3147.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Avet-Loiseau, F. Gerson, F. Magrangeas, S. Minvielle, J.-L. Harousseau, and R. Bataille
Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors
Blood,
November 15, 2001;
98(10):
3082 - 3086.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Shou, M. L. Martelli, A. Gabrea, Y. Qi, L. A. Brents, A. Roschke, G. Dewald, I. R. Kirsch, P. L. Bergsagel, and W. M. Kuehl
Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma
PNAS,
January 4, 2000;
97(1):
228 - 233.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Georgii-Hemming, T. Stromberg, E. T. Janson, M. Stridsberg, H. J. Wiklund, and K. Nilsson
The Somatostatin Analog Octreotide Inhibits Growth of Interleukin-6 (IL-6)-Dependent and IL-6-Independent Human Multiple Myeloma Cell Lines
Blood,
March 1, 1999;
93(5):
1724 - 1731.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Chesi, P. L. Bergsagel, O. O. Shonukan, M. L. Martelli, L. A. Brents, T. Chen, E. Schrock, T. Ried, and W. M. Kuehl
Frequent Dysregulation of the c-maf Proto-Oncogene at 16q23 by Translocation to an Ig Locus in Multiple Myeloma
Blood,
June 15, 1998;
91(12):
4457 - 4463.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
